查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957345

原發性免疫力缺乏市場－全球產業規模、佔有率、趨勢、機會、預測：按疾病、療法、地區和競爭對手分類，2021-2031年

Primary Immunodeficiency Disorders Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease, By Treatment, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球原發性免疫力缺乏市場預計將從 2025 年的 71.2 億美元成長到 2031 年的 106.2 億美元，複合年成長率為 6.89%。

原發性免疫力缺乏（PIDs）涵蓋多種遺傳異常，這些異常會損害免疫系統，使患者極易感染疾病和自體免疫疾病。這些疾病的治療主要依賴免疫球蛋白替代療法、預防性抗生素和造血幹細胞移植。新生兒篩檢計畫的廣泛應用和基因檢測的日益普及是推動該領域發展的關鍵因素，這兩項舉措共同提高了診斷率，並有助於早期發現需要終身治療性介入的患者。

市場概覽
預測期 2027-2031
市場規模：2025年 71.2億美元
市場規模：2031年 106.2億美元
複合年成長率：2026-2031年 6.89%
成長最快的細分市場 免疫球蛋白替代療法
最大的市場 北美洲

然而，血漿衍生療法的生產過程複雜且高成本，為市場擴充性帶來了巨大障礙，常常導致全球供不應求。而需要治療的新疾病變異株的快速發現，進一步加劇了這一困境。正如國際原發性免疫力缺乏患者組織在2024年指出的那樣，國際免疫學會聯合會已確認超過559種原發性免疫力缺乏疾病。疾病種類的日益多樣化，使得治療通訊協定的標準化更加複雜，並給本已有限的血漿資源帶來了更大的壓力。

市場促進因素

政府主導的新生兒篩檢計畫的擴展正成為市場成長的關鍵催化劑，使得在嚴重感染疾病發生之前儘早識別危及生命的缺陷成為可能。普遍篩檢通訊協定的實施顯著縮短了重症聯合免疫力缺乏（SCID）等疾病的診斷延遲，確保嬰兒能夠迅速獲得包括造血幹細胞移植在內的根治性治療。這一公共衛生領域的進步正在有效縮小重點地區疾病盛行率與實際診斷率之間的差距。例如，2024年5月，澳洲免疫力缺乏基金會宣布將SCID檢測納入所有州和地區的標準新生兒血斑篩檢計畫。這將系統性地擴大診斷網路，從而使需要終身護理的患者群體不斷成長。

同時，免疫球蛋白替代療法的日益普及推動了市場收入的成長，這得益於全球靜脈注射和皮下注射兩種給藥方式需求的不斷成長。隨著診斷率的提高，免疫力缺乏治療中對血漿衍生療法的依賴性日益增強，這要求生產商擴大其血漿採集和分離能力。根據 Griffols 公司於 2025 年 2 月發布的《2024 會計年度全年財務報告》，該公司免疫球蛋白業務成長加速，營收成長 15.3%，凸顯了強勁的基礎需求。這一積極趨勢在主要行業參與者中通用，CSL Limited 公司報告稱，其免疫球蛋白產品組合的銷售額在 2024 年成長了 20%，達到 56.6 億美元，凸顯了該治療領域巨大的經濟規模。

市場挑戰

血漿衍生療法的生產需要高度複雜的製程和大量的資金投入，這成為限制全球原發性免疫力缺乏市場擴張的主要瓶頸。與傳統藥物不同，免疫球蛋白替代療法依賴人類血漿這種有限的生物原料，需要嚴格且高成本的採集和分離過程。由於這些固有的生產限制，供應鏈無法快速回應全球需求的激增，導致產品反覆短缺。這些限制使得製造商無法有效擴大生產規模，儘管患者診斷率不斷提高，但收入成長和市場發展卻停滯不前。

該市場的脆弱性因過度依賴特定地區的原料供應而進一步加劇。根據血漿蛋白治療協會 (PPTA) 2024 年的數據，北美捐贈者提供的血漿佔全球整體生產所需血漿供應的 63% 以上，凸顯了嚴重的區域不平衡。這種對單一地區關鍵資源的過度依賴，一旦北美出現物流中斷、監管變化或勞動力短缺等問題，就會對全球治療藥物供應造成不成比例的影響。因此，供應鏈缺乏多樣性削弱了該行業確保治療藥物持續供應的能力，直接阻礙了市場的長期永續性。

市場趨勢

隨著居家治療中皮下注射免疫球蛋白（SCIG）的普及，治療模式正在發生根本性的轉變，更加強調患者的自主性，並減少對醫療機構的依賴。與需要頻繁就醫的傳統靜脈注射不同，先進的皮下注射系統使患者能夠在家中自行給藥，顯著提高了慢性疾病患者的生活品質。這一轉變對兒童患者尤其重要，因為減少就醫次數對於他們長期堅持治療至關重要。例如，2024年6月，武田製藥宣布加拿大衛生署已將HyQvia的適應症擴大至2至16歲的兒童。這使其成為該年齡層唯一一種允許每3至4週在家給藥的皮下注射免疫球蛋白製劑。

同時，該產業正從廣泛的免疫支持轉向針對特定基因突變的個人化醫療。臨床醫生擴大採用標靶療法，作用於特定的分子通路，例如與活化磷脂3-激酶Delta症候群（APDS）相關的PI3KδDelta通路，而不是僅依賴特異性替代標靶治療。這種精準的治療方法可以直接調節與特定基因缺陷相關的失控免疫反應，並改善罕見突變患者的臨床療效。根據Farming Group NV於2024年5月發布的2024年第一季財報，標靶治療Joenja的銷售額達到960萬美元，較上一季成長21%。這主要歸功於持續發現攜帶APDS確診基因標記的患者。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：原發性免疫力缺乏的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病特定類別（抗體缺乏症、細胞免疫力缺乏、先天免疫缺陷症、其他）
    • 治療方法（免疫球蛋白替代療法、抗生素療法、幹細胞/骨髓移植、基因療法等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美原發性免疫力缺乏市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲原發性免疫力缺乏市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區原發性免疫力缺乏市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲原發性免疫力缺乏市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲原發性免疫力缺乏市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球原發性免疫力缺乏市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • CSL Behring
  • Grifols
  • Takeda
  • Octapharma
  • Sanofi
  • Baxalta
  • Kamada
  • Sandoz
  • Baxter
  • Shire

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25300

The Global Primary Immunodeficiency Disorders Market is projected to expand from USD 7.12 Billion in 2025 to USD 10.62 Billion by 2031, registering a CAGR of 6.89%. Primary Immunodeficiency Disorders (PIDs) encompass a diverse array of hereditary genetic anomalies that compromise the immune system, leaving patients acutely vulnerable to serious infections and autoimmune conditions. Management of these disorders primarily depends on immunoglobulin replacement therapies, prophylactic antibiotic regimens, and hematopoietic stem cell transplantation. The sector's growth is fundamentally underpinned by the widespread adoption of newborn screening initiatives and the enhanced availability of genetic testing, which collectively boost diagnostic rates and facilitate the early identification of patients requiring lifelong therapeutic intervention.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.12 Billion
Market Size 2031USD 10.62 Billion
CAGR 2026-20316.89%
Fastest Growing SegmentImmunoglobulin Replacement Therapy
Largest MarketNorth America

Nevertheless, the market faces a substantial scalability hurdle due to the intricate and costly nature of manufacturing plasma-derived treatments, a factor that often results in global supply deficits. This strain is exacerbated by the rapid discovery of unique disease variants necessitating care. As noted by the International Patient Organisation for Primary Immunodeficiencies in 2024, the International Union of Immunological Societies classification has identified over 559 distinct types of primary immunodeficiency. This ongoing fragmentation of the disease landscape adds complexity to the standardization of treatment protocols and places further pressure on the already finite supply of essential plasma resources.

Market Driver

The broadening of government-mandated newborn screening programs serves as a pivotal catalyst for market expansion by enabling the early identification of life-threatening defects prior to the onset of severe infections. Implementing universal screening protocols drastically minimizes diagnostic delays for conditions such as severe combined immunodeficiency (SCID), ensuring infants promptly receive curative treatments like hematopoietic stem cell transplantation. This public health evolution is effectively narrowing the disparity between disease prevalence and actual diagnosis in major regions. For instance, the Immunodeficiency Foundation Australia announced in May 2024 that every Australian state and territory has successfully incorporated SCID testing into their standard newborn bloodspot screening panels, systematically enlarging the diagnostic net and, consequently, the patient population requiring lifelong care.

Simultaneously, the rising utilization of immunoglobulin replacement therapies is driving market revenue, supported by vigorous global demand for both intravenous and subcutaneous administration methods. As diagnostic rates rise, the dependence on plasma-derived therapies for managing immune deficiencies grows, necessitating that manufacturers expand their plasma collection and fractionation capacities. According to Grifols' 'Full Year Results 2024' report released in February 2025, the company's immunoglobulin division saw accelerated growth with a 15.3% increase in revenue, highlighting strong underlying demand. This positive trend is mirrored across major industry players; CSL Limited reported in 2024 that sales of their immunoglobulin portfolio rose by 20% to $5.66 billion, underscoring the significant financial magnitude of this therapeutic sector.

Market Challenge

The immense complexity and significant capital investment required for manufacturing plasma-derived therapies represent a critical bottleneck that directly constrains the expansion of the Global Primary Immunodeficiency Disorders Market. Unlike traditional pharmaceuticals, immunoglobulin replacement therapies depend on human plasma as a finite biological raw material, necessitating strict and expensive collection and fractionation procedures. This inherent rigidity in manufacturing results in a supply chain that struggles to adapt quickly to sudden spikes in global demand, leading to recurring product shortages. Such limitations hinder manufacturers from effectively scaling production volumes, thereby stalling revenue growth and market development despite increasing patient diagnosis rates.

This market vulnerability is further compounded by a heavy reliance on specific geographic regions for raw material sourcing. Data from the Plasma Protein Therapeutics Association in 2024 indicates that North American donors contributed over 63% of the global plasma supply utilized for manufacturing, revealing a severe regional imbalance. Because of this dependence on a single region for the majority of critical resources, any logistical disruptions, regulatory shifts, or labor challenges in North America disproportionately affect the global availability of therapies. Consequently, this insufficient diversification in the supply chain impairs the industry's capacity to ensure consistent treatment access, directly inhibiting the market's long-term sustainability.

Market Trends

The growing transition toward subcutaneous immunoglobulin (SCIG) for home-based care is fundamentally altering treatment paradigms by emphasizing patient autonomy and decreasing reliance on clinical settings. In contrast to traditional intravenous methods that require frequent hospital visits, advanced facilitated subcutaneous systems permit self-administration at home, greatly improving the quality of life for those with chronic conditions. This shift is especially significant for pediatric patients, for whom reducing the burden of medical appointments is essential for long-term adherence. For example, Takeda announced in June 2024 that Health Canada had expanded HyQvia's authorization to include children aged two to sixteen, making it the sole subcutaneous immune globulin infusion for this age group that supports home administration every three to four weeks.

In parallel, the industry is moving beyond broad-spectrum immune support toward personalized medicine designed for specific genetic mutations. Clinicians are increasingly utilizing targeted therapies that address unique molecular pathways-such as the PI3K delta signaling pathway involved in activated phosphoinositide 3-kinase delta syndrome (APDS)-instead of relying exclusively on non-specific replacement therapies. This precision approach directly modulates the dysregulated immune responses linked to distinct genetic defects, thereby enhancing clinical outcomes for patients with rare variants. According to Pharming Group N.V.'s 'First Quarter 2024 Financial Results' from May 2024, revenue for the targeted therapy Joenja reached $9.6 million, a 21% sequential increase attributed to the ongoing identification of patients with confirmed genetic markers for APDS.

Key Market Players

  • CSL Behring
  • Grifols
  • Takeda
  • Octapharma
  • Sanofi
  • Baxalta
  • Kamada
  • Sandoz
  • Baxter
  • Shire

Report Scope

In this report, the Global Primary Immunodeficiency Disorders Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Primary Immunodeficiency Disorders Market, By Disease

  • Antibody Deficiency
  • Cellular Immunodeficiency
  • Innate Immune Disorders
  • Others

Primary Immunodeficiency Disorders Market, By Treatment

  • Immunoglobulin Replacement Therapy
  • Antibiotic Therapy
  • Stem Cell/Bone Marrow Transplantation
  • Gene Therapy
  • Others

Primary Immunodeficiency Disorders Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Primary Immunodeficiency Disorders Market.

Available Customizations:

Global Primary Immunodeficiency Disorders Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Primary Immunodeficiency Disorders Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Others)
    • 5.2.2. By Treatment (Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell/Bone Marrow Transplantation, Gene Therapy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Primary Immunodeficiency Disorders Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease
    • 6.2.2. By Treatment
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Primary Immunodeficiency Disorders Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease
        • 6.3.1.2.2. By Treatment
    • 6.3.2. Canada Primary Immunodeficiency Disorders Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease
        • 6.3.2.2.2. By Treatment
    • 6.3.3. Mexico Primary Immunodeficiency Disorders Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease
        • 6.3.3.2.2. By Treatment

7. Europe Primary Immunodeficiency Disorders Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease
    • 7.2.2. By Treatment
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Primary Immunodeficiency Disorders Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease
        • 7.3.1.2.2. By Treatment
    • 7.3.2. France Primary Immunodeficiency Disorders Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease
        • 7.3.2.2.2. By Treatment
    • 7.3.3. United Kingdom Primary Immunodeficiency Disorders Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease
        • 7.3.3.2.2. By Treatment
    • 7.3.4. Italy Primary Immunodeficiency Disorders Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease
        • 7.3.4.2.2. By Treatment
    • 7.3.5. Spain Primary Immunodeficiency Disorders Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease
        • 7.3.5.2.2. By Treatment

8. Asia Pacific Primary Immunodeficiency Disorders Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease
    • 8.2.2. By Treatment
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Primary Immunodeficiency Disorders Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease
        • 8.3.1.2.2. By Treatment
    • 8.3.2. India Primary Immunodeficiency Disorders Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease
        • 8.3.2.2.2. By Treatment
    • 8.3.3. Japan Primary Immunodeficiency Disorders Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease
        • 8.3.3.2.2. By Treatment
    • 8.3.4. South Korea Primary Immunodeficiency Disorders Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease
        • 8.3.4.2.2. By Treatment
    • 8.3.5. Australia Primary Immunodeficiency Disorders Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease
        • 8.3.5.2.2. By Treatment

9. Middle East & Africa Primary Immunodeficiency Disorders Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease
    • 9.2.2. By Treatment
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Primary Immunodeficiency Disorders Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease
        • 9.3.1.2.2. By Treatment
    • 9.3.2. UAE Primary Immunodeficiency Disorders Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease
        • 9.3.2.2.2. By Treatment
    • 9.3.3. South Africa Primary Immunodeficiency Disorders Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease
        • 9.3.3.2.2. By Treatment

10. South America Primary Immunodeficiency Disorders Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease
    • 10.2.2. By Treatment
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Primary Immunodeficiency Disorders Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease
        • 10.3.1.2.2. By Treatment
    • 10.3.2. Colombia Primary Immunodeficiency Disorders Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease
        • 10.3.2.2.2. By Treatment
    • 10.3.3. Argentina Primary Immunodeficiency Disorders Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease
        • 10.3.3.2.2. By Treatment

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Primary Immunodeficiency Disorders Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. CSL Behring
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Grifols
  • 15.3. Takeda
  • 15.4. Octapharma
  • 15.5. Sanofi
  • 15.6. Baxalta
  • 15.7. Kamada
  • 15.8. Sandoz
  • 15.9. Baxter
  • 15.10. Shire

16. Strategic Recommendations

17. About Us & Disclaimer